WILBEXUS
LIVE

Serial Number

98397723

Owner

Celgene Corporation

Attorney

Marilyn F. Kelly

Filing Date

Feb 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

WILBEXUS Trademark

Serial Number: 98397723

WILBEXUS is a trademark filed by Celgene Corporation on February 8, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

February 8, 2024

Registration Date

Not Registered

Published for Opposition

January 21, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use, namely, for the treatment of neuropsychiatric disorders; Pharmaceutical preparations for human use, namely, therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors, diagnostic radiopharmaceutical preparations, diagnostic agents, preparations and substances for medical purposes; Pharmaceutical preparations for human use, namely, radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, radio-isotope markers for therapeutic or diagnostic use.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 25, 2026 EXRA
SOU EXTENSION 2 GRANTED
Feb 24, 2026 EX2G
SOU EXTENSION 2 FILED
Feb 24, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 24, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 27, 2025 EXRA
SOU EXTENSION 1 GRANTED
Aug 26, 2025 EX1G
SOU EXTENSION 1 FILED
Aug 26, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 26, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 18, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 15, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 30, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 3, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 3, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 3, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 3, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 3, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 3, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 28, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 7, 2024 NWOS
NEW APPLICATION ENTERED
Feb 8, 2024 NWAP